The Korea Times close
National
  • Politics
  • Diplomacy
  • Defense
  • Labor & Environment
  • Law & Crime
  • Health & Welfare
  • Embassy
  • Seoul & Provinces
  • Education
  • Foreign Communities
  • Obituaries
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Finance
  • Policies
  • Economy
  • Markets
  • Banks
  • Non-banks
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
Lifestyle
  • Arts
  • Books
  • Travel & Cuisine
  • Trend
  • Fashion
  • Around Town
  • Fortune Telling
Entertainment
  • K-pop
  • K-dramas & Shows
  • Movies
  • Music
  • Performances
  • Asia Model Festival
Sports
  • Football
  • Golf
  • Baseball
  • Other Sports
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Video
  • On the Spot
  • Feature
  • News
Photos
  • Photo News
  • Darkroom
Community
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Thu, February 25, 2021 | 20:35
Asia Pacific
AstraZeneca COVID-19 vaccine set to be approved in India: Reuters
Posted : 2021-01-01 19:32
Updated : 2021-01-01 19:32
Mail
Print Preview
Font Size Up
Font Size Down
Vials with a sticker reading, 'COVID-19 / Coronavirus vaccine / Injection only' and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken on Oct. 31, 2020. Reuters
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken on Oct. 31, 2020. Reuters

India's drug regulator is set to approve on Friday a coronavirus vaccine developed by AstraZeneca and Oxford University for emergency use, three sources with knowledge of the matter said.

The decision would pave the way for the vaccine's rollout in the world's second-most populous country which, after the United States, has the highest number of COVID-19 infections in the world.

Britain and Argentina have already authorised the vaccine for urgent public use.

India's Central Drugs Standard Control Organization (CDSCO), whose experts were meeting for the second time this week, could also approve a vaccine locally developed by Bharat Biotech, two of the sources said on condition of anonymity.

"Both AstraZeneca and Bharat Biotech will get approval today," said one of the sources. "All preparations are on with today's date in mind."

The other sources were less certain about Bharat Biotech's prospects.

"We are hopeful," another source said about the vaccine developed with the government-run Indian Council of Medical Research.

A CDSCO representative declined to comment. The group is meeting a day ahead of a nationwide trial run https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1685048 for vaccine delivery in the country with more than 10 million coronavirus infections.

More than 50 million doses of the AstraZeneca vaccine have already been stockpiled by its local manufacturer, Serum Institute of India (SII), and one of the sources said the shots could start to be transported from cold storage to Indian states as early as Saturday.

SII said in an email it would "wait for the final approval to come" before commenting.

India's government said on Wednesday that Pfizer Inc had sought more time to present data for emergency authorisation of a vaccine it has developed with Germany's BioNTech. (Reuters)











 
 
  • K League star Ki Sung-yueng denies sexual assault allegations
  • All overseas arrivals required to submit negative PCR test results
  • Haute couture designer Kay Kim speaks about SM's girl band debut costume, her brand
  • Korea reports 1st population decline in 2020; total fertility rate hits new record of 0.84
  • Victims still reeling from traumatic past, yet bullies forgetful
  • Earth is suffering [PHOTOS]
  • Hyundai to replace Kona EV batteries
  • [ANALYSIS] Is Samsung Electronics losing competence in NAND?
  • New virus cases rebound to over 400 ahead of vaccine rollout
  • South Korea raises wartime sex slavery issue at UN
  • B.A.P Himchan sentenced to 10 months in prison for sexual assault B.A.P Himchan sentenced to 10 months in prison for sexual assault
  • Agency refuses to confirm report that Jennie and G-Dragon are dating Agency refuses to confirm report that Jennie and G-Dragon are dating
  • [INTERVIEW] 'Minari' actor Han Ye-ri recalls why the film is special to her [INTERVIEW] 'Minari' actor Han Ye-ri recalls why the film is special to her
  • Online streamer under fire for 'thoughtless' behavior in Brazil Online streamer under fire for 'thoughtless' behavior in Brazil
  • 'Beauty Water' becomes 1st Korean animated film to win award at Boston Sci-Fi Film Festival 'Beauty Water' becomes 1st Korean animated film to win award at Boston Sci-Fi Film Festival
DARKROOM
  • Earth is suffering [PHOTOS]

    Earth is suffering [PHOTOS]

  • NASA's Perseverance rover is landing on Mars

    NASA's Perseverance rover is landing on Mars

  • Fun in the snow, sledding for everyone

    Fun in the snow, sledding for everyone

  • Our children deserve better: Part 3

    Our children deserve better: Part 3

  • Mass COVID-19 vaccination campaign starts: Part 2

    Mass COVID-19 vaccination campaign starts: Part 2

  • About Korea Times
  • CEO Message
  • Times History
  • Content Sales
  • Media Kit
  • Contact Us
  • Location
  • Privacy Statement
  • Terms of Service
  • Mobile Service
  • RSS Service
  • 고충처리인
  • hankookilbo
  • Dongwha Group
  • Code of Ethics
Copyright